Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: A cohort study

American Journal of Medicine

Volumn 128, Issue 6, 2015, Pages 653.e7-653.e16

  Kim, Seoyoung C ^a,b   Schneeweiss, Sebastian ^a,b   Choudhry, Niteesh ^a   Liu, Jun ^a   Glynn, Robert J ^a   Solomon, Daniel H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Allopurinol; Cardiovascular disease; Febuxostat; Gout; Heart failure; Myocardial infarction; Stroke; Xanthine oxidase inhibitor

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; URIC ACID; ANTIGOUT AGENT; XANTHINE OXIDASE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GOUT; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERURICEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPENSITY SCORE; URIC ACID BLOOD LEVEL; ANTAGONISTS AND INHIBITORS; COMPLICATION; HEART DISEASES; MIDDLE AGED; RISK FACTOR;

ADULT; COHORT STUDIES; FEMALE; GOUT; GOUT SUPPRESSANTS; HEART DISEASES; HUMANS; HYPERURICEMIA; MALE; MIDDLE AGED; RISK FACTORS; XANTHINE OXIDASE;

EID: 84930383321     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2015.01.013     Document Type: Article

References (39)

1. Y. Zhu, B. Pandya, and H. Choi Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008 Arthritis Rheum 63 2011 3136 3141
2. H.K. Choi, D.B. Mount, and A.M. Reginato Pathogenesis of gout Ann Intern Med 143 2005 499 516
3. L. Annemans, E. Spaepen, and M. Gaskin Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005 Ann Rheum Dis 67 2008 960 966
4. S.C. Kim, B.M. Schmidt, and J.M. Franklin Clinical and health care use characteristics of patients newly prescribed allopurinol, febuxostat and colchicine for gout Arthritis Care Res (Hoboken) 65 2013 2008 2014
5. J.A. Singh, and V. Strand Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans Ann Rheum Dis 67 2008 1310 1316
6. Y. Zhu, B. Pandya, and H. Choi Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008 Am J Med 125 2012 679 687
7. P.C. Grayson, S.Y. Kim, M. LaValley, and H.K. Choi Hyperuricemia and incident hypertension: a systematic review and meta-analysis Arthritis Care Res (Hoboken) 63 2011 102 110
8. S.Y. Kim, J.P. Guevara, and K.M. Kim Hyperuricemia and risk of stroke: a systematic review and meta-analysis Arthritis Rheum 61 2009 885 892
9. S.Y. Kim, J.P. Guevara, and K.M. Kim Hyperuricemia and coronary heart disease: a systematic review and meta-analysis Arthritis Care Res (Hoboken) 62 2010 170 180
10. D. Khanna, J.D. Fitzgerald, and P.P. Khanna 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia Arthritis Care Res (Hoboken) 64 2012 1431 1446
11. A. Kelkar, A. Kuo, and W.H. Frishman Allopurinol as a cardiovascular drug Cardiol Rev 19 2011 265 271
12. I. Gotsman, A. Keren, C. Lotan, and D.R. Zwas Changes in uric acid levels and allopurinol use in chronic heart failure: association with improved survival J Card Fail 18 2012 694 701
13. Grimaldi-Bensouda L, Alpérovitch A, Aubrun E, et al. Impact of allopurinol on risk of myocardial infarction. Ann Rheum Dis, in press.
14. D.I. Feig, B. Soletsky, and R.J. Johnson Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial JAMA 300 2008 924 932
15. H. Terawaki, M. Nakayama, and E. Miyazawa Effect of allopurinol on cardiovascular incidence among hypertensive nephropathy patients: the Gonryo study Clin Exp Nephrol 17 2012 554
16. L. Wei, I.S. Mackenzie, Y. Chen, A.D. Struthers, and T.M. MacDonald Impact of allopurinol use on urate concentration and cardiovascular outcome Br J Clin Pharmacol 71 2011 600 607
17. M.M. Givertz, D.L. Mann, and K.L. Lee Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study Circ Heart Fail 6 2013 862 868
18. G. Thanassoulis, J. Brophy, H. Richard, and L. Pilote Gout, allopurinol use, and heart failure outcomes Arch Intern Med 170 2010 1358 1364
19. N.L. Edwards Febuxostat: a new treatment for hyperuricaemia in gout Rheumatology (Oxford) 48 suppl 2 2009 ii15 ii19
20. H.R.J. Schumacher, M.A. Becker, and R.L. Wortmann Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial Arthritis Rheum 59 2008 1540 1548
21. S.E. Andrade, L.R. Harrold, and J. Tjia A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data Pharmacoepidemiol Drug Saf 21 suppl 1 2012 100 128
22. J.S. Saczynski, S.E. Andrade, and L.R. Harrold A systematic review of validated methods for identifying heart failure using administrative data Pharmacoepidemiol Drug Saf 21 suppl 1 2012 129 140
23. Y. Kiyota, S. Schneeweiss, and R.J. Glynn Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records Am Heart J 148 2004 99 104
24. N.N. Choma, M.R. Griffin, and R.L. Huang An algorithm to identify incident myocardial infarction using Medicaid data Pharmacoepidemiol Drug Saf 18 2009 1064 1071
25. J.J. Gagne, R.J. Glynn, J. Avorn, R. Levin, and S. Schneeweiss A combined comorbidity score predicted mortality in elderly patients better than existing scores J Clin Epidemiol 64 2011 749 759
26. D. Rubin Estimating causal effects from large data sets using propensity scores Ann Intern Med 127 1997 757 763
27. P.C. Austin The performance of different propensity score methods for estimating marginal odds ratios Stat Med 26 2007 3078 3094
28. P.C. Austin Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations Biom J 51 2009 171 184
29. J.A. Rassen, R.J. Glynn, M.A. Brookhart, and S. Schneeweiss Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples Am J Epidemiol 173 2011 1404 1413
30. S. Schneeweiss, J.A. Rassen, and R.J. Glynn High-dimensional propensity score adjustment in studies of treatment effects using health care claims data Epidemiology 20 2009 512 522
31. D. Kleinbaum, and M. Klein Evaluating the proportional hazards Assumption M. Gail, K. Krickberg, J. Samet, A. Tsiatis, W. Wong, Survival Analysis: A Self-Learning Text 3rd ed 2012 Springer New York
32. S. Schneeweiss, J.A. Rassen, and R.J. Glynn Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments BMC Med Res Methodol 12 2012 180
33. R. Halpern, R.R. Mody, M.J. Fuldeore, P.A. Patel, and T.R. Mikuls Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis Curr Med Res Opin 25 2009 1711 1719
34. L.R. Harrold, K.M. Mazor, and A. Negron Primary care providers' knowledge, beliefs and treatment practices for gout: results of a physician questionnaire Rheumatology (Oxford) 52 2013 1623 1629
35. W.A. Ray Evaluating medication effects outside of clinical trials: new-user designs Am J Epidemiol 158 2003 915 920
36. M. Kanbay, B. Huddam, and A. Azak A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function Clin J Am Soc Nephrol 6 2011 1887 1894
37. G. Melendez-Ramirez, O. Perez-Mendez, C. Lopez-Osorio, J. Kuri-Alfaro, and N. Espinola-Zavaleta Effect of the treatment with allopurinol on the endothelial function in patients with hyperuricemia Endocr Res 37 2012 1 6
38. W. Doehner, N. Schoene, and M. Rauchhaus Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies Circulation 105 2002 2619 2624
39. N. Engberding, S. Spiekermann, and A. Schaefer Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug? Circulation 110 2004 2175 2179